Imiquimod: Potential risk of an immunostimulant
- 1 May 2004
- journal article
- case report
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 45 (2), 123-124
- https://doi.org/10.1111/j.1440-0960.2004.00060.x
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathwayNature Immunology, 2002
- EditorialInternational Journal of Dermatology, 2002
- Topical immunomodulators—progress towards treating inflammation, infection, and cancerThe Lancet Infectious Diseases, 2001
- A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patientsAIDS, 1999
- Review Article Imiquimod applied topically: a novel immune response modifier and new class of drugInternational Journal of Immunopharmacology, 1999
- Topical ImiquimodDrugs, 1999
- Cytokine Induction in Hairless Mouse and Rat Skin After Topical Application of the Immune Response Modifiers Imiquimod and S-28463Journal of Investigative Dermatology, 1998
- Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigsAntimicrobial Agents and Chemotherapy, 1994